Physician profile
Alexandra Noel Grace
NPI 1295291938
$21,266.07
in general payments reported to CMS, 2019-2025
9 companies · $8,119 in 2025
The $8,119 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $3,940 · 2023: $3,776 · 2024: $5,420 · 2025: $8,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $2,610 · Food and Beverage: $2,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,116.00 |
| Travel and Lodging | $2,609.79 |
| Food and Beverage | $2,588.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17,845.85 | 2022-2025 | |
| Ptc Therapeutics, INC. | $2,330.70 | 2025 | Sephience |
| Biomarin Pharmaceutical INC. | $494.19 | 2021-2025 | Voxzogo 1.2mg, Palynziq |
| Chiesi USA, INC. | $249.96 | 2025 | Elfabrio |
| Amgen INC. | $125.00 | 2024 | Ravicti |
| Horizon Therapeutics Plc | $107.68 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $63.89 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.